Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Shimai Pharmaceutical Co. Ltd. currently has 1 pending office action. This single action is assigned to 1 distinct examiner. The busiest examiner for this portfolio is HAM, JIEUN, who is responsible for 1 busiest examiner pending action. This matches the total volume of 1 pending office action. Because there is only a single distinct examiner involved, the entire current prosecution workload is concentrated under this individual. The data also shows 0 distinct art units for this matter. This singular focus requires a targeted approach to the specific examination style of HAM, JIEUN.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAM, JIEUN | 1 | 50.0% | +8.8% |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691036 | ANTIBODIES AGAINST GPC3 AND USES THEREOF | HAM, JIEUN | — | §112 | Non-Final OA | — | Pending | Mar 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial